Single-dose zoliflodacin (ETX0914) for treatment of urogenital gonorrhea

New England Journal of Medicine

Volumn 379, Issue 19, 2018, Pages 1835-1845

  Taylor, Stephanie N ^h   Marrazzo, Jeanne ^a,i   Batteiger, Byron E ^b   Hook, Edward W ⁱ   Seña, Arlene C ^c   Long, Jill ^e   Wierzbicki, Michael R ^f   Kwak, Hannah ^e   Johnson, Shacondra M ^d   Lawrence, Kenneth ^g   Mueller, John ^j  

^a UNIVERSITY OF WASHINGTON   (United States)

^b INDIANA UNIVERSITY   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d FAMILY HEALTH INTERNATIONAL   (United States)

^e Biostatistics Research Branch National Institution of Allergy and Infectious Diseases   (United States)

^f EMMES   (United States)

^g Entasis Therapeutics   (United States)

^h LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

ⁱ University of Alabama at Birmingham   (United States)

^j NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CEFTRIAXONE; CIPROFLOXACIN; PENICILLIN DERIVATIVE; ZOLIFLODACIN; ANTIINFECTIVE AGENT; BARBITURIC ACID DERIVATIVE; SPIRO COMPOUND;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL CLEARANCE; BACTERIUM CULTURE; BACTERIUM ISOLATE; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; GASTROINTESTINAL DISEASE; GONORRHEA; HUMAN; INTENTION TO TREAT ANALYSIS; LACK OF DRUG EFFECT; MALE; MINIMUM INHIBITORY CONCENTRATION; NEISSERIA GONORRHOEAE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT OUTCOME; ADOLESCENT; CONTROLLED STUDY; DRUG EFFECT; INTRAMUSCULAR DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PHARYNX DISEASE; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RECTUM DISEASE; SEXUALITY; UROGENITAL TRACT DISEASE; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; BARBITURATES; CEFTRIAXONE; FEMALE; FEMALE UROGENITAL DISEASES; GONORRHEA; HUMANS; INJECTIONS, INTRAMUSCULAR; INTENTION TO TREAT ANALYSIS; MALE; MALE UROGENITAL DISEASES; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; NEISSERIA GONORRHOEAE; PHARYNGEAL DISEASES; RECTAL DISEASES; SEXUAL PARTNERS; SPIRO COMPOUNDS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85056380793     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1706988     Document Type: Article

References (35)

1. Sexually transmitted disease surveillance 2017. Atlanta: Centers for Disease Control and Prevention https://www.cdc.gov/std/stats/default.htm.
2. Unemo M, Shafer WM. Antibiotic resistance in Neisseria gonorrhoeae: origin, evolution, and lessons learned for the future. Ann N Y Acad Sci 2011;1230:E19-E28.
3. Kirkcaldy RD, Ballard RC, Dowell D. Gonococcal resistance: are cephalosporins next? Curr Infect Dis Rep 2011;13: 196-204.
4. Cámara J, Serra J, Ayats J, et al. Molecular characterization of two high-level ceftriaxone-resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain. J Antimicrob Chemother 2012;67:1858-60.
5. Allen VG, Mitterni L, Seah C, et al. Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada. JAMA 2013;309:163-70.
6. Soge OO, Harger D, Schafer S, et al. Emergence of increased azithromycin resistance during unsuccessful treatment of Neisseria gonorrhoeae infection with azithromycin (Portland, OR, 2011). Sex Transm Dis 2012;39:877-9.
7. McLean CA, Wang SA, Hoff GL, et al. The emergence of Neisseria gonorrhoeae with decreased susceptibility to azithromycin in Kansas City, Missouri, 1999 to 2000. Sex Transm Dis 2004;31:73-8.
8. Unemo M, Golparian D, Nicholas R, Ohnishi M, Gallay A, Sednaoui P. High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother 2012;56: 1273-80.
9. Bolan GA, Sparling PF, Wasserheit JN. The emerging threat of untreatable gonococcal infection. N Engl J Med 2012;366: 485-7.
10. Ohnishi M, Golparian D, Shimuta K, et al. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother 2011;55: 3538-45.
11. Unemo M, Nicholas RA. Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea. Future Microbiol 2012;7:1401-22.
12. Ison CA, Hussey J, Sankar KN, Evans J, Alexander S. Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010. Euro Surveill 2011;16: 19833.
13. Unemo M, Golparian D, Syversen G, Vestrheim DF, Moi H. Two cases of verified clinical failures using internationally recommended first-line cefixime for gonorrhoea treatment, Norway, 2010. Euro Surveill 2010;15:19721.
14. Terkelsen D, Tolstrup J, Johnsen CH, et al. Multidrug-resistant Neisseria gonorrhoeae infection with ceftriaxone resistance and intermediate resistance to azithromycin, Denmark, 2017. Euro Surveill 2017; 22(42).
15. Katz AR, Komeya AY, Kirkcaldy RD, et al. Cluster of Neisseria gonorrhoeae isolates with high-level azithromycin resistance and decreased ceftriaxone susceptibility, Hawaii, 2016. Clin Infect Dis 2017;65:918-23.
16. Lefebvre B, Martin I, Demczuk W, et al. Ceftriaxone-resistant Neisseria gonorrhoeae, Canada, 2017. Emerg Infect Dis 2018;24(2).
17. Barbee LA, Soge OO, Katz DA, Dom-browski JC, Holmes KK, Golden MR. Increases in Neisseria gonorrhoeae with reduced susceptibility to azithromycin among men who have sex with men in Seattle, King County, Washington, 2012-2016. Clin Infect Dis 2018;66:712-8.
18. Kirkcaldy RD, Harvey A, Papp JR, et al. Neisseria gonorrhoeae antimicrobial susceptibility surveillance ' the Gonococcal Isolate Surveillance Project, 27 sites, United States, 2014. MMWR Surveill Summ 2016;65(SS-7):1-19.
19. Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluo-roquinolones no longer recommended for treatment of gonococcal infections. MMWR Morb Mortal Wkly Rep 2007;56:332-6.
20. Workowski KA, Berman S. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010;59(RR-12): 1-110.
21. Update to CDC's sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infection. MMWR Morb Mortal Wkly Rep 2012;61:590-4.
22. Basarab GS, Kern GH, McNulty J, et al. Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial type II topoisomerases. Sci Rep 2015;5:11827.
23. AZ0914 Investigator's Brochure. Edition number 2, 25/JUL2014. Cambridge, England: AstraZeneca, 2014.
24. Bignell C, Unemo, M. 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS 2013;24:85-92.
25. Bignell C, Fitzgerald M. UK national guideline for the management of gonorrhoea in adults, 2011. Int J STD AIDS 2011;22:541-7.
26. Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015; 64(RR-3):1-137.
27. Performance standards for antimicrobial susceptibility testing: twenty-third informational supplement. CLSI document M100-S23. Vol. 33. No. 1. Wayne, PA: Clinical and Laboratory Standards Institute, January 2013:100-2.
28. Fleiss JL, Levin B, Paik MC. Statistical methods for rates and proportions. 3rd ed. Hoboken, NJ: John Wiley, 2003.
29. Manavi K, Young H, McMillan A. The outcome of oropharyngeal gonorrhoea treatment with different regimens. Int J STD AIDS 2005;16:68-70.
30. Sathia L, Ellis B, Phillip S, Winston A, Smith A. Pharyngeal gonorrhoea ' is dual therapy the way forward? Int J STD AIDS 2007;18:647-8.
31. Ota KV, Fisman DN, Tamari IE, et al. Incidence and treatment outcomes of pharyngeal Neisseria gonorrhoeae and Chlamydia trachomatis infections in men who have sex with men: a 13-year retrospective cohort study. Clin Infect Dis 2009;48:1237-43.
32. Moran JS, Levine WC. Drugs of choice for the treatment of uncomplicated gonococcal infections. Clin Infect Dis 1995;20: Suppl 1:S47-S65.
33. Handsfield HH, Dalu ZA, Martin DH, Douglas JM Jr, McCarty JM, Schlossberg D. Multicenter trial of single-dose azithromycin vs. ceftriaxone in the treatment of uncomplicated gonorrhea. Sex Transm Dis 1994;21:107-11.
34. Kirkcaldy RD, Weinstock HS, Moore PC, et al. The efficacy and safety of genta-micin plus azithromycin and gemifloxa-cin plus azithromycin as treatment of uncomplicated gonorrhea. Clin Infect Dis 2014;59:1083-91.
35. Hook EW III, Golden M, Jamieson BD, et al. A phase 2 trial of oral solithromycin 1200 mg or 1000 mg as a single-dose oral therapy for uncomplicated gonorrhea. Clin Infect Dis 2015;61:1043-8.